Peginterferon alfa-2a
Class
Cytokines
Subclass
Interferons
Generic name
Peginterferon alfa-2a, pegylated interferon alfa-2a
Brand names
Pegasys®
Common formulations
Solution for injection
Dosage and administration
Adults patients
HBV infection • Chronic
HCV infection • Chronic
HDV infection • Chronic • Off-label
Indications for use
Labeled indications
Adults
Children
Off-label indications
Adults
Safety risks
Boxed warnings
Exacerbation of autoimmune disorders
Exacerbation of cerebrovascular events
Infections
Neuropsychiatric adverse events
Contraindications
Hypersensitivity to alpha interferons, including peginterferon alfa-2a, or its components
AIH
Warnings and precautions
Acute pancreatitis
Cardiovascular adverse events
Colitis
Endocrine disorders
Growth suppression
Hepatitis exacerbation
Myelosuppression
Peripheral neuropathy
Pulmonary disorders
Visual impairment
Specific populations
Renal impairment
CrCl ≥ 30 mL/min
CrCl < 30 mL/min
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B3
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
May potentially cause adverse effects in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource